The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers

被引:109
作者
Smyth, HDC [1 ]
机构
[1] Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Chapel Hill, NC 27599 USA
关键词
asthma; hydrofluoroalkane; aerosol; chlorofluorocarbon; vapor pressure; particle size; lung deposition;
D O I
10.1016/S0169-409X(03)00079-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are a multitude of formulation factors to consider when developing a pMDI. Evaluation of each of these variables has been performed over the years, but there has been an abundance of different approaches in the determination of the effects on device performance. Thus, although much is known about pMDI on the empirical level, a systematic approach has clearly been missing. With the ratification of the Montreal Protocol and the introduction of alternative propellant systems, the opportunity to establish relationships between different levels of testing, such as in vitro measurements and in vivo outcomes, and in vivo assessments and clinical outcomes, has arrived. This review outlines research efforts that have focused on the formulation of propellant-driven metered dose inhalers using alternative propellants. These formulation factors, including device characteristics, are reviewed with respect to the performance of MDIs. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:807 / 828
页数:22
相关论文
共 152 条
[1]   AN OVERVIEW OF THE TOXICOLOGY OF HFA-134A (1,1,1,2-TETRAFLUOROETHANE) [J].
ALEXANDER, DJ ;
LIBRETTO, SE .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1995, 14 (09) :715-720
[2]  
ALTIERE RJ, 1996, INHALATION AEROSOLS, V94
[3]  
Anderson P J, 2000, Respir Care, V45, P737
[4]  
[Anonymous], J BIOPHARM SCI
[5]  
[Anonymous], 1992, DRUGS PHARM SCI
[6]  
[Anonymous], 1998, GUID IND MET DOS INH
[7]  
[Anonymous], 1966, HEALTH PHYS
[8]   A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration [J].
Argenti, D ;
Shah, B ;
Heald, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (05) :516-526
[9]  
ASHURST IC, 1996, Patent No. 6131566
[10]  
ATKINS P, 1990, RDD, V2